{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T21:08:04Z","timestamp":1767042484070,"version":"3.48.0"},"reference-count":147,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CURR MED SCI"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11596-025-00121-4","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T09:25:34Z","timestamp":1763371534000},"page":"1288-1303","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["T-Cell Responses and T-Cell-Based Therapy in Acute Myeloid Leukemia"],"prefix":"10.1007","volume":"45","author":[{"given":"Ze-han","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5046-1321","authenticated-orcid":false,"given":"Ran","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"issue":"7","key":"121_CR1","doi-asserted-by":"publisher","first-page":"e441","DOI":"10.1038\/bcj.2016.50","volume":"6","author":"I De Kouchkovsky","year":"2016","unstructured":"De Kouchkovsky I, Abdul-Hay M. \u2018Acute myeloid leukemia: a comprehensive review and 2016 update\u2019. Blood Cancer Journal. 2016;6(7):e441\u2013e441.","journal-title":"Blood Cancer Journal."},{"issue":"1","key":"121_CR2","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13045-021-01062-w","volume":"14","author":"H Liu","year":"2021","unstructured":"Liu H. Emerging agents and regimens for AML. J Hematol Oncol. 2021;14(1):49.","journal-title":"J Hematol Oncol."},{"issue":"2","key":"121_CR3","doi-asserted-by":"publisher","first-page":"308","DOI":"10.3324\/haematol.2022.280801","volume":"108","author":"S Kayser","year":"2023","unstructured":"Kayser S, Levis MJ. The clinical impact of the molecular landscape of acute myeloid leukemia. Haematologica. 2023;108(2):308\u2013320.","journal-title":"Haematologica."},{"issue":"Suppl 1","key":"121_CR4","doi-asserted-by":"publisher","first-page":"8957","DOI":"10.4081\/hr.2020.8957","volume":"12","author":"T Haferlach","year":"2020","unstructured":"Haferlach T. Advancing leukemia diagnostics: Role of Next Generation Sequencing (NGS) in acute myeloid leukemia. Hematol Rep. 2020;12(Suppl 1):8957.","journal-title":"Hematol Rep."},{"issue":"2","key":"121_CR5","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.annonc.2022.11.004","volume":"34","author":"A Bazinet","year":"2023","unstructured":"Bazinet A, Kantarjian HM. Moving toward individualized target-based therapies in acute myeloid leukemia. Ann Oncol. 2023;34(2):141\u2013151.","journal-title":"Ann Oncol."},{"unstructured":"Pelcovits A, Niroula R. Acute Myeloid Leukemia: A Review. R I Med J (2013). 2020;103(3):38\u201340.","key":"121_CR6"},{"issue":"1","key":"121_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13045-017-0543-7","volume":"11","author":"X Yang","year":"2018","unstructured":"Yang X, Wang J. Precision therapy for acute myeloid leukemia. J Hematol Oncol. 2018;11(1):3.","journal-title":"J Hematol Oncol."},{"issue":"25","key":"121_CR8","doi-asserted-by":"publisher","first-page":"14331","DOI":"10.1073\/pnas.1916206117","volume":"117","author":"AJ Lamble","year":"2020","unstructured":"Lamble AJ, Kosaka Y, Laderas T, et al. Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia. Proc Natl Acad Sci USA. 2020;117(25):14331\u201314341.","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"5","key":"121_CR9","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/s41423-021-00655-2","volume":"18","author":"G Liu","year":"2021","unstructured":"Liu G, Rui W, Zhao X, et al. Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment. Cell Mol Immunol. 2021;18(5):1085\u20131095.","journal-title":"Cell Mol Immunol."},{"issue":"4","key":"121_CR10","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1172\/JCI129204","volume":"130","author":"L Vago","year":"2020","unstructured":"Vago L, Gojo I. Immune escape and immunotherapy of acute myeloid leukemia. J Clin Invest. 2020;130(4):1552\u20131564.","journal-title":"J Clin Invest."},{"issue":"10","key":"121_CR11","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1038\/s41375-022-01666-2","volume":"36","author":"R Ranieri","year":"2022","unstructured":"Ranieri R, Pianigiani G, Sciabolacci S, et al. Current status and future perspectives in targeted therapy of NPM1-mutated AML. Leukemia. 2022;36(10):2351\u20132367.","journal-title":"Leukemia."},{"key":"121_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.686156","volume":"11","author":"L Xu","year":"2021","unstructured":"Xu L, Liu L, Yao D, et al. PD-1 and TIGIT Are Highly Co-Expressed on CD8(+) T Cells in AML Patient Bone Marrow. Front Oncol. 2021;11:686156.","journal-title":"Front Oncol."},{"issue":"1","key":"121_CR13","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s40164-022-00353-3","volume":"11","author":"W Zhou","year":"2022","unstructured":"Zhou W, Yu J, Li Y, et al. Neoantigen-specific TCR-T cell-based immunotherapy for acute myeloid leukemia. Exp Hematol Oncol. 2022;11(1):100.","journal-title":"Exp Hematol Oncol."},{"issue":"3","key":"121_CR14","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1200\/JCO.2011.41.1116","volume":"31","author":"S Hofmann","year":"2013","unstructured":"Hofmann S, Gotz M, Schneider V, et al. Donor lymphocyte infusion induces polyspecific CD8(+) T-cell responses with concurrent molecular remission in acute myeloid leukemia with NPM1 mutation. J Clin Oncol. 2013;31(3):e44\u201347.","journal-title":"J Clin Oncol."},{"issue":"2","key":"121_CR15","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1172\/JCI97482","volume":"129","author":"DI van der Lee","year":"2019","unstructured":"van der Lee DI, Reijmers RM, Honders MW, et al. Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia. J Clin Invest. 2019;129(2):774\u2013785.","journal-title":"J Clin Invest."},{"issue":"7","key":"121_CR16","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41419-019-1717-8","volume":"10","author":"Q Sun","year":"2019","unstructured":"Sun Q, Zhang X, Wang L, et al. T-cell receptor gene therapy targeting melanoma-associated antigen-A4 by silencing of endogenous TCR inhibits tumor growth in mice and human. Cell Death Dis. 2019;10(7):475.","journal-title":"Cell Death Dis."},{"issue":"21","key":"121_CR17","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1182\/blood-2017-06-786129","volume":"130","author":"KT Mueller","year":"2017","unstructured":"Mueller KT, Maude SL, Porter DL, et al. Cellular kinetics of CTL019 in relapsed\/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia. Blood. 2017;130(21):2317\u20132325.","journal-title":"Blood."},{"issue":"16","key":"121_CR18","doi-asserted-by":"publisher","first-page":"8996","DOI":"10.3390\/ijms22168996","volume":"22","author":"T Haslauer","year":"2021","unstructured":"Haslauer T, Greil R, Zaborsky N, et al. CAR T-Cell Therapy in Hematological Malignancies. Int J Mol Sci. 2021;22(16):8996.","journal-title":"Int J Mol Sci."},{"issue":"11","key":"121_CR19","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1016\/j.ccell.2023.09.010","volume":"41","author":"S Haubner","year":"2023","unstructured":"Haubner S, Mansilla-Soto J, Nataraj S, et al. Cooperative CAR targeting to selectively eliminate AML and minimize escape. Cancer Cell. 2023;41(11):1871\u20131891.e1876.","journal-title":"Cancer Cell."},{"issue":"8","key":"121_CR20","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1007\/s00262-023-03454-y","volume":"72","author":"XN Gao","year":"2023","unstructured":"Gao XN, Su YF, Li MY, et al. Single-center phase 2 study of PD-1 inhibitor combined with DNA hypomethylation agent + CAG regimen in patients with relapsed\/refractory acute myeloid leukemia. Cancer Immunol Immunother. 2023;72(8):2769\u20132782.","journal-title":"Cancer Immunol Immunother."},{"issue":"1","key":"121_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003392","volume":"10","author":"M Goswami","year":"2022","unstructured":"Goswami M, Gui G, Dillon LW, et al. Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia. J Immunother Cancer. 2022;10(1):e003392.","journal-title":"J Immunother Cancer."},{"issue":"4","key":"121_CR22","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.3390\/ijms22041944","volume":"22","author":"R Tabata","year":"2021","unstructured":"Tabata R, Chi S, Yuda J, et al. Emerging Immunotherapy for Acute Myeloid Leukemia. Int J Mol Sci. 2021;22(4):1994.","journal-title":"Int J Mol Sci."},{"issue":"2","key":"121_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.113794","volume":"43","author":"B Bassani","year":"2024","unstructured":"Bassani B, Simonetti G, Cancila V, et al. ZEB1 shapes AML immunological niches, suppressing CD8 T cell activity while fostering Th17 cell expansion. Cell Rep. 2024;43(2):113794.","journal-title":"Cell Rep."},{"doi-asserted-by":"crossref","unstructured":"Desai PN, Wang B, Fonseca A, et al. Single-Cell Profiling of CD8+ T Cells in Acute Myeloid Leukemia Reveals a Continuous Spectrum of Differentiation and Clonal Hyperexpansion. Cancer Immunol Res. 2023:CIR-22-0961.","key":"121_CR24","DOI":"10.1158\/2326-6066.c.6684963.v3"},{"key":"121_CR25","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.blre.2018.12.001","volume":"34","author":"Y Liu","year":"2019","unstructured":"Liu Y, Bewersdorf JP, Stahl M, et al. Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era? Blood Rev. 2019;34:67\u201383.","journal-title":"Blood Rev."},{"key":"121_CR26","doi-asserted-by":"publisher","first-page":"1169144","DOI":"10.3389\/fimmu.2023.1169144","volume":"14","author":"H Zhou","year":"2023","unstructured":"Zhou H, Jia B, Annageldiyev C, et al. CD26(low)PD-1(+) CD8 T cells are terminally exhausted and associated with leukemia progression in acute myeloid leukemia. Front Immunol. 2023;14:1169144.","journal-title":"Front Immunol."},{"issue":"11","key":"121_CR27","first-page":"5726","volume":"11","author":"Y Chen","year":"2021","unstructured":"Chen Y, Feng Z, Kuang X, et al. Increased lactate in AML blasts upregulates TOX expression, leading to exhaustion of CD8(+) cytolytic T cells. Am J Cancer Res. 2021;11(11):5726\u20135742.","journal-title":"Am J Cancer Res."},{"issue":"11","key":"121_CR28","first-page":"3973","volume":"10","author":"Z Feng","year":"2020","unstructured":"Feng Z, Fang Q, Kuang X, et al. Clonal expansion of bone marrow CD8(+) T cells in acute myeloid leukemia patients at new diagnosis and after chemotherapy. Am J Cancer Res. 2020;10(11):3973\u20133989.","journal-title":"Am J Cancer Res."},{"issue":"1","key":"121_CR29","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1084\/jem.20042541","volume":"202","author":"Y Kato","year":"2005","unstructured":"Kato Y, Iwama A, Tadokoro Y, et al. Selective activation of STAT5 unveils its role in stem cell self-renewal in normal and leukemic hematopoiesis. J Exp Med. 2005;202(1):169\u2013179.","journal-title":"J Exp Med."},{"issue":"1","key":"121_CR30","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s41392-023-01605-2","volume":"8","author":"ZW Huang","year":"2023","unstructured":"Huang ZW, Zhang XN, Zhang L, et al. STAT5 promotes PD-L1 expression by facilitating histone lactylation to drive immunosuppression in acute myeloid leukemia. Signal Transduct Target Ther. 2023;8(1):391.","journal-title":"Signal Transduct Target Ther."},{"issue":"7728","key":"121_CR31","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/s41586-018-0615-z","volume":"562","author":"M Deng","year":"2018","unstructured":"Deng M, Gui X, Kim J, et al. LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration. Nature. 2018;562(7728):605\u2013609.","journal-title":"Nature."},{"issue":"3","key":"121_CR32","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/s41423-019-0321-2","volume":"17","author":"Z Li","year":"2020","unstructured":"Li Z, Deng M, Huang F, et al. LILRB4 ITIMs mediate the T cell suppression and infiltration of acute myeloid leukemia cells. Cell Mol Immunol. 2020;17(3):272\u2013282.","journal-title":"Cell Mol Immunol."},{"issue":"1","key":"121_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2021.166268","volume":"1868","author":"J Zhang","year":"2022","unstructured":"Zhang J, Peng Y, He Y, et al. GPX1-associated prognostic signature predicts poor survival in patients with acute myeloid leukemia and involves in immunosuppression. Biochim Biophys Acta Mol Basis Dis. 2022;1868(1):166268.","journal-title":"Biochim Biophys Acta Mol Basis Dis."},{"issue":"1","key":"121_CR34","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s00262-023-03594-1","volume":"73","author":"R Towers","year":"2024","unstructured":"Towers R, Trombello L, Fusenig M, et al. Bone marrow-derived mesenchymal stromal cells obstruct AML-targeting CD8(+) clonal effector and CAR T-cell function while promoting a senescence-associated phenotype. Cancer Immunol Immunother. 2024;73(1):8.","journal-title":"Cancer Immunol Immunother."},{"issue":"12","key":"121_CR35","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1016\/j.immuni.2021.11.015","volume":"54","author":"DY Oh","year":"2021","unstructured":"Oh DY, Fong L. Cytotoxic CD4(+) T cells in cancer: Expanding the immune effector toolbox. Immunity. 2021;54(12):2701\u20132711.","journal-title":"Immunity."},{"key":"121_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.702726","volume":"12","author":"EN Scott","year":"2021","unstructured":"Scott EN, Gocher AM, Workman CJ, et al. Regulatory T Cells: Barriers of Immune Infiltration Into the Tumor Microenvironment. Front Immunol. 2021;12:702726.","journal-title":"Front Immunol."},{"issue":"5","key":"121_CR37","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s12282-020-01079-y","volume":"27","author":"LA Solis-Castillo","year":"2020","unstructured":"Solis-Castillo LA, Garcia-Romo GS, Diaz-Rodriguez A, et al. Tumor-infiltrating regulatory T cells, CD8\/Treg ratio, and cancer stem cells are correlated with lymph node metastasis in patients with early breast cancer. Breast Cancer. 2020;27(5):837\u2013849.","journal-title":"Breast Cancer."},{"issue":"1","key":"121_CR38","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1186\/s12885-020-06961-8","volume":"20","author":"Y Wan","year":"2020","unstructured":"Wan Y, Zhang C, Xu Y, et al. Hyperfunction of CD4 CD25 regulatory T cells in de novo acute myeloid leukemia. BMC Cancer. 2020;20(1):472.","journal-title":"BMC Cancer."},{"issue":"6","key":"121_CR39","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1002\/ijc.25791","volume":"129","author":"Z Shenghui","year":"2011","unstructured":"Shenghui Z, Yixiang H, Jianbo W, et al. Elevated frequencies of CD4(+) CD25(+) CD127lo regulatory T cells is associated to poor prognosis in patients with acute myeloid leukemia. Int J Cancer. 2011;129(6):1373\u20131381.","journal-title":"Int J Cancer."},{"issue":"9","key":"121_CR40","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/s00262-020-02591-y","volume":"69","author":"M Dehghani","year":"2020","unstructured":"Dehghani M, Kalani M, Golmoghaddam H, et al. Aberrant peripheral blood CD4(+) CD25(+) FOXP3(+) regulatory T cells\/T helper-17 number is associated with the outcome of patients with lymphoma. Cancer Immunol Immunother. 2020;69(9):1917\u20131928.","journal-title":"Cancer Immunol Immunother."},{"key":"121_CR41","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.3389\/fimmu.2018.01274","volume":"9","author":"M Wang","year":"2018","unstructured":"Wang M, Zhang C, Tian T, et al. Increased Regulatory T Cells in Peripheral Blood of Acute Myeloid Leukemia Patients Rely on Tumor Necrosis Factor (TNF)-alpha-TNF Receptor-2 Pathway. Front Immunol. 2018;9:1274.","journal-title":"Front Immunol."},{"key":"121_CR42","doi-asserted-by":"publisher","first-page":"1165973","DOI":"10.3389\/fimmu.2023.1165973","volume":"14","author":"M Khelfa","year":"2023","unstructured":"Khelfa M, Leclerc M, Kerbrat S, et al. Divergent CD4(+) T-cell profiles are associated with anti-HLA alloimmunization status in platelet-transfused AML patients. Front Immunol. 2023;14:1165973.","journal-title":"Front Immunol."},{"issue":"19","key":"121_CR43","doi-asserted-by":"publisher","first-page":"5084","DOI":"10.1182\/blood-2011-07-365817","volume":"118","author":"C Ustun","year":"2011","unstructured":"Ustun C, Miller JS, Munn DH, et al. Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation? Blood. 2011;118(19):5084\u20135095.","journal-title":"Blood."},{"key":"121_CR44","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.0105-2896.2006.00427.x","volume":"212","author":"S Sakaguchi","year":"2006","unstructured":"Sakaguchi S, Ono M, Setoguchi R, et al. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev. 2006;212:8\u201327.","journal-title":"Immunol Rev."},{"key":"121_CR45","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/j.0105-2896.2006.00415.x","volume":"212","author":"EM Shevach","year":"2006","unstructured":"Shevach EM, DiPaolo RA, Andersson J, et al. The lifestyle of naturally occurring CD4+ CD25+ Foxp3+ regulatory T cells. Immunol Rev. 2006;212:60\u201373.","journal-title":"Immunol Rev."},{"issue":"5","key":"121_CR46","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202200251R","volume":"36","author":"F Qian","year":"2022","unstructured":"Qian F, Arner BE, Kelly KM, et al. Interleukin-4 treatment reduces leukemia burden in acute myeloid leukemia. FASEB J. 2022;36(5):e22328.","journal-title":"FASEB J."},{"doi-asserted-by":"crossref","unstructured":"Uhl FM, Chen S, O'Sullivan D, et al. Metabolic reprogramming of donor T cells enhances graft-versus-leukemia effects in mice and humans. Sci Transl Med. 2020;12(567):eabb8969.","key":"121_CR47","DOI":"10.1126\/scitranslmed.abb8969"},{"issue":"4","key":"121_CR48","first-page":"231","volume":"6","author":"LM Tuyt","year":"1995","unstructured":"Tuyt LM, Dokter WH, Esselink MT, et al. Divergent effects of IL-10 and IL-4 on the proliferation and growth factor secretion by acute myeloblastic leukemic cells. Eur Cytokine Netw. 1995;6(4):231\u2013235.","journal-title":"Eur Cytokine Netw."},{"issue":"3","key":"121_CR49","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/leu.2017.261","volume":"32","author":"P Pena-Martinez","year":"2018","unstructured":"Pena-Martinez P, Eriksson M, Ramakrishnan R, et al. Interleukin 4 induces apoptosis of acute myeloid leukemia cells in a Stat6-dependent manner. Leukemia. 2018;32(3):588\u2013596.","journal-title":"Leukemia."},{"issue":"13","key":"121_CR50","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1182\/blood-2016-08-736405","volume":"129","author":"ER Finch","year":"2017","unstructured":"Finch ER, Tukaramrao DB, Goodfield LL, et al. Activation of PPARgamma by endogenous prostaglandin J(2) mediates the antileukemic effect of selenium in murine leukemia. Blood. 2017;129(13):1802\u20131810.","journal-title":"Blood."},{"issue":"3","key":"121_CR51","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jcyt.2020.01.001","volume":"22","author":"Y Wang","year":"2020","unstructured":"Wang Y, Sun X, Yuan S, et al. Interleukin-1beta inhibits normal hematopoietic expansion and promotes acute myeloid leukemia progression via the bone marrow niche. Cytotherapy. 2020;22(3):127\u2013134.","journal-title":"Cytotherapy."},{"issue":"6","key":"121_CR52","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1182\/blood-2012-01-404699","volume":"120","author":"L Barreyro","year":"2012","unstructured":"Barreyro L, Will B, Bartholdy B, et al. Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. Blood. 2012;120(6):1290\u20131298.","journal-title":"Blood."},{"issue":"1","key":"121_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2022.113112","volume":"415","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Guo H, Zhang Z, et al. IL-6 promotes chemoresistance via upregulating CD36 mediated fatty acids uptake in acute myeloid leukemia. Exp Cell Res. 2022;415(1):113112.","journal-title":"Exp Cell Res."},{"issue":"3","key":"121_CR54","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.cyto.2012.12.023","volume":"61","author":"B Sanchez-Correa","year":"2013","unstructured":"Sanchez-Correa B, Bergua JM, Campos C, et al. Cytokine profiles in acute myeloid leukemia patients at diagnosis: survival is inversely correlated with IL-6 and directly correlated with IL-10 levels. Cytokine. 2013;61(3):885\u2013891.","journal-title":"Cytokine."},{"issue":"3","key":"121_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.100961","volume":"4","author":"R Lameris","year":"2023","unstructured":"Lameris R, Ruben JM, Iglesias-Guimarais V, et al. A bispecific T cell engager recruits both type 1 NKT and Vgamma9Vdelta2-T cells for the treatment of CD1d-expressing hematological malignancies. Cell Rep Med. 2023;4(3):100961.","journal-title":"Cell Rep Med."},{"issue":"7","key":"121_CR56","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s12272-019-01139-8","volume":"42","author":"EA Bae","year":"2019","unstructured":"Bae EA, Seo H, Kim IK, et al. Roles of NKT cells in cancer immunotherapy. Arch Pharm Res. 2019;42(7):543\u2013548.","journal-title":"Arch Pharm Res."},{"issue":"2","key":"121_CR57","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/leu.2016.210","volume":"31","author":"W Herr","year":"2017","unstructured":"Herr W, Eichinger Y, Beshay J, et al. HLA-DPB1 mismatch alleles represent powerful leukemia rejection antigens in CD4 T-cell immunotherapy after allogeneic stem-cell transplantation. Leukemia. 2017;31(2):434\u2013445.","journal-title":"Leukemia."},{"issue":"1","key":"121_CR58","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/j.1365-2141.2005.05843.x","volume":"132","author":"M Matsushita","year":"2006","unstructured":"Matsushita M, Yamazaki R, Ikeda H, et al. Possible involvement of allogeneic antigens recognised by donor-derived CD4 cytotoxic T cells in selective GVL effects after stem cell transplantation of patients with haematological malignancy. Br J Haematol. 2006;132(1):56\u201365.","journal-title":"Br J Haematol."},{"issue":"4","key":"121_CR59","doi-asserted-by":"publisher","DOI":"10.1172\/JCI177663","volume":"134","author":"M Kronenberg","year":"2024","unstructured":"Kronenberg M, Engel I. NKT cells in the antitumor response: the beta version? J Clin Invest. 2024;134(4):e177663.","journal-title":"J Clin Invest."},{"key":"121_CR60","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.3389\/fimmu.2018.01969","volume":"9","author":"AK Singh","year":"2018","unstructured":"Singh AK, Tripathi P, Cardell SL. Type II NKT Cells: An Elusive Population With Immunoregulatory Properties. Front Immunol. 2018;9:1969.","journal-title":"Front Immunol."},{"key":"121_CR61","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.3389\/fimmu.2018.01266","volume":"9","author":"Y Kinjo","year":"2018","unstructured":"Kinjo Y, Takatsuka S, Kitano N, et al. Functions of CD1d-Restricted Invariant Natural Killer T Cells in Antimicrobial Immunity and Potential Applications for Infection Control. Front Immunol. 2018;9:1266.","journal-title":"Front Immunol."},{"issue":"12","key":"121_CR62","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/nri3328","volume":"12","author":"J Rossjohn","year":"2012","unstructured":"Rossjohn J, Pellicci DG, Patel O, et al. Recognition of CD1d-restricted antigens by natural killer T cells. Nat Rev Immunol. 2012;12(12):845\u2013857.","journal-title":"Nat Rev Immunol."},{"issue":"20","key":"121_CR63","doi-asserted-by":"publisher","first-page":"5174","DOI":"10.3390\/cancers13205174","volume":"13","author":"A Nelson","year":"2021","unstructured":"Nelson A, Lukacs JD, Johnston B. The Current Landscape of NKT Cell Immunotherapy and the Hills Ahead. Cancers (Basel). 2021;13(20):5174.","journal-title":"Cancers (Basel)."},{"key":"121_CR64","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.3389\/fimmu.2018.01838","volume":"9","author":"M Terabe","year":"2018","unstructured":"Terabe M, Berzofsky JA. Tissue-Specific Roles of NKT Cells in Tumor Immunity. Front Immunol. 2018;9:1838.","journal-title":"Front Immunol."},{"key":"121_CR65","doi-asserted-by":"publisher","first-page":"543","DOI":"10.3389\/fimmu.2014.00543","volume":"5","author":"FC Robertson","year":"2014","unstructured":"Robertson FC, Berzofsky JA, Terabe M. NKT cell networks in the regulation of tumor immunity. Front Immunol. 2014;5:543.","journal-title":"Front Immunol."},{"issue":"6","key":"121_CR66","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1097\/CJI.0000000000000171","volume":"40","author":"CL Boeck","year":"2017","unstructured":"Boeck CL, Amberger DC, Doraneh-Gard F, et al. Significance of Frequencies, Compositions, and\/or Antileukemic Activity of (DC-stimulated) Invariant NKT, NK and CIK Cells on the Outcome of Patients With AML, ALL and CLL. J Immunother. 2017;40(6):224\u2013248.","journal-title":"ALL and CLL. J Immunother."},{"issue":"8","key":"121_CR67","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1007\/s00432-012-1251-x","volume":"138","author":"CAE Najera","year":"2012","unstructured":"Najera CAE, Cervantes LA, Retiguin FP, et al. Low number of invariant NKT cells is associated with poor survival in acute myeloid leukemia. J Cancer Res Clin Oncol. 2012;138(8):1427\u20131432.","journal-title":"J Cancer Res Clin Oncol."},{"issue":"3","key":"121_CR68","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s00262-022-03268-4","volume":"72","author":"V Stavrou","year":"2023","unstructured":"Stavrou V, Fultang L, Booth S, et al. Invariant NKT cells metabolically adapt to the acute myeloid leukaemia environment. Cancer Immunol Immunother. 2023;72(3):543\u2013560.","journal-title":"Cancer Immunol Immunother."},{"key":"121_CR69","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.3389\/fimmu.2018.01817","volume":"9","author":"H Schmid","year":"2018","unstructured":"Schmid H, Schneidawind C, Jahnke S, et al. Culture-Expanded Human Invariant Natural Killer T Cells Suppress T-Cell Alloreactivity and Eradicate Leukemia. Front Immunol. 2018;9:1817.","journal-title":"Front Immunol."},{"issue":"2","key":"121_CR70","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007981","volume":"12","author":"A Rao","year":"2024","unstructured":"Rao A, Agrawal A, Borthakur G, et al. Gamma delta T cells in acute myeloid leukemia: biology and emerging therapeutic strategies. J Immunother Cancer. 2024;12(2):e007981.","journal-title":"J Immunother Cancer."},{"issue":"3","key":"121_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e25254","volume":"10","author":"VK Pathak","year":"2024","unstructured":"Pathak VK, Singh I, Sharma B, et al. Unveiling the role of NK cells, NKT-like cells, and gammadelta cells in pathogenesis of type 1 reactions in leprosy. Heliyon. 2024;10(3):e25254.","journal-title":"Heliyon."},{"issue":"3","key":"121_CR72","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1182\/blood-2012-06-435503","volume":"121","author":"J Richter","year":"2013","unstructured":"Richter J, Neparidze N, Zhang L, et al. Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma. Blood. 2013;121(3):423\u2013430.","journal-title":"Blood."},{"issue":"11","key":"121_CR73","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1084\/jem.20022227","volume":"198","author":"M Terabe","year":"2003","unstructured":"Terabe M, Matsui S, Park JM, et al. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med. 2003;198(11):1741\u20131752.","journal-title":"J Exp Med."},{"issue":"17","key":"121_CR74","doi-asserted-by":"publisher","first-page":"5518","DOI":"10.3390\/jcm12175518","volume":"12","author":"P Sudul","year":"2023","unstructured":"Sudul P, Piatkowska-Jakubas B, Pawlinski L, et al. The Complexities of Diagnosis with Co-Existing Gaucher Disease and Hemato-Oncology-A Case Report and Review of the Literature. J Clin Med. 2023;12(17):5518.","journal-title":"J Clin Med."},{"issue":"3","key":"121_CR75","doi-asserted-by":"publisher","first-page":"62","DOI":"10.14740\/jh655","volume":"9","author":"E Jamal","year":"2020","unstructured":"Jamal E, Azmy E, Ayed M, et al. Clinical Impact of Percentage of Natural Killer Cells and Natural Killer-Like T Cell Population in Acute Myeloid Leukemia. J Hematol. 2020;9(3):62\u201370.","journal-title":"J Hematol."},{"key":"121_CR76","doi-asserted-by":"publisher","first-page":"1009709","DOI":"10.3389\/fimmu.2022.1009709","volume":"13","author":"S Liang","year":"2022","unstructured":"Liang S, Dong T, Yue K, et al. Identification of the immunosuppressive effect of gammadelta T cells correlated to bone morphogenetic protein 2 in acute myeloid leukemia. Front Immunol. 2022;13:1009709.","journal-title":"Front Immunol."},{"issue":"8","key":"121_CR77","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1038\/s41375-021-01122-7","volume":"35","author":"R Ganesan","year":"2021","unstructured":"Ganesan R, Chennupati V, Ramachandran B, et al. Selective recruitment of gammadelta T cells by a bispecific antibody for the treatment of acute myeloid leukemia. Leukemia. 2021;35(8):2274\u20132284.","journal-title":"Leukemia."},{"key":"121_CR78","doi-asserted-by":"publisher","first-page":"658","DOI":"10.3389\/fimmu.2018.00658","volume":"9","author":"HH Van Acker","year":"2018","unstructured":"Van Acker HH, Anguille S, De Reu H, et al. Interleukin-15-Cultured Dendritic Cells Enhance Anti-Tumor Gamma Delta T Cell Functions through IL-15 Secretion. Front Immunol. 2018;9:658.","journal-title":"Front Immunol."},{"key":"121_CR79","doi-asserted-by":"publisher","first-page":"1294555","DOI":"10.3389\/fimmu.2023.1294555","volume":"14","author":"GM Branella","year":"2023","unstructured":"Branella GM, Lee JY, Okalova J, et al. Ligand-based targeting of c-kit using engineered gammadelta T cells as a strategy for treating acute myeloid leukemia. Front Immunol. 2023;14:1294555.","journal-title":"Front Immunol."},{"key":"121_CR80","doi-asserted-by":"publisher","first-page":"1202950","DOI":"10.3389\/fimmu.2023.1202950","volume":"14","author":"A Kent","year":"2023","unstructured":"Kent A, Crump LS, Davila E. Beyond alphabeta T cells: NK, iNKT, and gammadeltaT cell biology in leukemic patients and potential for off-the-shelf adoptive cell therapies for AML. Front Immunol. 2023;14:1202950.","journal-title":"Front Immunol."},{"issue":"12","key":"121_CR81","doi-asserted-by":"publisher","first-page":"4399","DOI":"10.1007\/s00262-023-03574-5","volume":"72","author":"Q Peng","year":"2023","unstructured":"Peng Q, Huang R, Wang H, et al. Immune characteristics and prognostic implications of mucosal-associated invariant T cells in acute myeloid leukemia. Cancer Immunol Immunother. 2023;72(12):4399\u20134414.","journal-title":"Cancer Immunol Immunother."},{"key":"121_CR82","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.3389\/fimmu.2020.01556","volume":"11","author":"M Ioannidis","year":"2020","unstructured":"Ioannidis M, Cerundolo V, Salio M. The Immune Modulating Properties of Mucosal-Associated Invariant T Cells. Front Immunol. 2020;11:1556.","journal-title":"Front Immunol."},{"key":"121_CR83","doi-asserted-by":"publisher","first-page":"1369236","DOI":"10.3389\/fimmu.2024.1369236","volume":"15","author":"M Yigit","year":"2024","unstructured":"Yigit M, Basoglu OF, Unutmaz D. Mucosal-associated invariant T cells in cancer: dual roles, complex interactions and therapeutic potential. Front Immunol. 2024;15:1369236.","journal-title":"Front Immunol."},{"issue":"46","key":"121_CR84","doi-asserted-by":"publisher","first-page":"76274","DOI":"10.18632\/oncotarget.11187","volume":"7","author":"EJ Won","year":"2016","unstructured":"Won EJ, Ju JK, Cho YN, et al. Clinical relevance of circulating mucosal-associated invariant T cell levels and their anti-cancer activity in patients with mucosal-associated cancer. Oncotarget. 2016;7(46):76274\u201376290.","journal-title":"Oncotarget."},{"key":"121_CR85","doi-asserted-by":"publisher","first-page":"1160943","DOI":"10.3389\/fimmu.2023.1160943","volume":"14","author":"E Treiner","year":"2023","unstructured":"Treiner E. Mucosal-associated invariant T cells in hematological malignancies: Current knowledge, pending questions. Front Immunol. 2023;14:1160943.","journal-title":"Front Immunol."},{"issue":"4","key":"121_CR86","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s00262-021-03037-9","volume":"71","author":"T Comont","year":"2022","unstructured":"Comont T, Nicolau-Travers ML, Bertoli S, et al. MAIT cells numbers and frequencies in patients with acute myeloid leukemia at diagnosis: association with cytogenetic profile and gene mutations. Cancer Immunol Immunother. 2022;71(4):875\u2013887.","journal-title":"Cancer Immunol Immunother."},{"issue":"1","key":"121_CR87","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41408-023-00975-8","volume":"14","author":"FM Tien","year":"2024","unstructured":"Tien FM, Yao CY, Tsai XC, et al. Dysregulated immune and metabolic pathways are associated with poor survival in adult acute myeloid leukemia with CEBPA bZIP in-frame mutations. Blood Cancer J. 2024;14(1):15.","journal-title":"Blood Cancer J."},{"issue":"1","key":"121_CR88","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2174\/1389201019666180418095526","volume":"19","author":"AN Miliotou","year":"2018","unstructured":"Miliotou AN, Papadopoulou LC. CAR T-cell Therapy: A New Era in Cancer Immunotherapy. Curr Pharm Biotechnol. 2018;19(1):5\u201318.","journal-title":"Curr Pharm Biotechnol."},{"issue":"10","key":"121_CR89","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1182\/blood.2019002779","volume":"135","author":"X He","year":"2020","unstructured":"He X, Feng Z, Ma J, et al. Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia. Blood. 2020;135(10):713\u2013723.","journal-title":"Blood."},{"issue":"5","key":"121_CR90","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.ccell.2022.04.001","volume":"40","author":"MB Leick","year":"2022","unstructured":"Leick MB, Silva H, Scarfo I, et al. Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia. Cancer Cell. 2022;40(5):494\u2013508.e495.","journal-title":"Cancer Cell."},{"issue":"11","key":"121_CR91","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1038\/s41422-022-00721-y","volume":"32","author":"Y Hu","year":"2022","unstructured":"Hu Y, Zhou Y, Zhang M, et al. Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed\/refractory CD7-positive hematological malignancies: a phase I clinical study. Cell Res. 2022;32(11):995\u20131007.","journal-title":"Cell Res."},{"issue":"10","key":"121_CR92","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1038\/s41375-024-02351-2","volume":"38","author":"D Atar","year":"2024","unstructured":"Atar D, Ruoff L, Mast AS, et al. Rational combinatorial targeting by adapter CAR-T-cells (AdCAR-T) prevents antigen escape in acute myeloid leukemia. Leukemia. 2024;38(10):2183\u20132195.","journal-title":"Leukemia."},{"issue":"3","key":"121_CR93","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0320443","volume":"20","author":"RS Leigh","year":"2025","unstructured":"Leigh RS, Kaynak BL, Ruskoaho H, et al. Development and comparison of single FLT3-inhibitors to dual FLT3\/TAF1-inhibitors as an anti-leukemic approach. PLoS One. 2025;20(3):e0320443.","journal-title":"PLoS One."},{"issue":"1","key":"121_CR94","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40164-025-00605-y","volume":"14","author":"M Yao","year":"2025","unstructured":"Yao M, Yan W, Wang Y, et al. IHCH9033, a novel class I HDAC inhibitor, synergizes with FLT3 inhibitor and rescues quizartinib resistance in FLT3-ITD AML via enhancing DNA damage response. Exp Hematol Oncol. 2025;14(1):15.","journal-title":"Exp Hematol Oncol."},{"issue":"2","key":"121_CR95","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1182\/blood.2019001239","volume":"135","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Wei AH. How I treat acute myeloid leukemia in the era of new drugs. Blood. 2020;135(2):85\u201396.","journal-title":"Blood."},{"issue":"3","key":"121_CR96","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s40259-021-00477-8","volume":"35","author":"S Fiorenza","year":"2021","unstructured":"Fiorenza S, Turtle CJ. CAR-T Cell Therapy for Acute Myeloid Leukemia: Preclinical Rationale, Current Clinical Progress, and Barriers to Success. BioDrugs. 2021;35(3):281\u2013302.","journal-title":"BioDrugs."},{"issue":"9","key":"121_CR97","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005400","volume":"10","author":"MD Sanchez","year":"2022","unstructured":"Sanchez MD, Tirado N, Mensurado S, et al. Generation and proof-of-concept for allogeneic CD123 CAR-Delta One T (DOT) cells in acute myeloid leukemia. J Immunother Cancer. 2022;10(9):e005400.","journal-title":"J Immunother Cancer."},{"issue":"8","key":"121_CR98","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1182\/blood.2020006921","volume":"137","author":"S Willier","year":"2021","unstructured":"Willier S, Rothamel P, Hastreiter M, et al. CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy. Blood. 2021;137(8):1037\u20131049.","journal-title":"Blood."},{"issue":"4","key":"121_CR99","first-page":"338","volume":"23","author":"H Wang","year":"2025","unstructured":"Wang H, Feng S, Zhu Y, et al. The tandem CD33-CLL1 CAR-T as an approach to treat acute myeloid leukemia. Blood Transfus. 2025;23(4):338\u2013347.","journal-title":"Blood Transfus."},{"doi-asserted-by":"crossref","unstructured":"Wang QJ, Yu Z, Hanada KI et al. Preclinical Evaluation of Chimeric Antigen Receptors Targeting CD70-Expressing Cancers. Clin Cancer Res. 2017;23(9):2267\u20132276.","key":"121_CR100","DOI":"10.1158\/1078-0432.CCR-16-1421"},{"key":"121_CR101","doi-asserted-by":"publisher","first-page":"1389227","DOI":"10.3389\/fimmu.2024.1389227","volume":"15","author":"X Miao","year":"2024","unstructured":"Miao X, Shuai Y, Han Y, et al. Case report: Donor-derived CLL-1 chimeric antigen receptor T-cell therapy for relapsed\/refractory acute myeloid leukemia bridging to allogeneic hematopoietic stem cell transplantation after remission. Front Immunol. 2024;15:1389227.","journal-title":"Front Immunol."},{"issue":"1","key":"121_CR102","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13045-022-01308-1","volume":"15","author":"X Jin","year":"2022","unstructured":"Jin X, Zhang M, Sun R, et al. First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed\/refractory acute myeloid leukemia. J Hematol Oncol. 2022;15(1):88.","journal-title":"J Hematol Oncol."},{"issue":"1","key":"121_CR103","doi-asserted-by":"publisher","first-page":"2248826","DOI":"10.1080\/2162402X.2023.2248826","volume":"12","author":"X Jin","year":"2023","unstructured":"Jin X, Xie D, Sun R, et al. CAR-T cells dual-target CD123 and NKG2DLs to eradicate AML cells and selectively target immunosuppressive cells. Oncoimmunology. 2023;12(1):2248826.","journal-title":"Oncoimmunology."},{"doi-asserted-by":"crossref","unstructured":"Stefik P, Annusova A, Lakatos B, et al. Targeting acute myeloid leukemia cells by CD33 receptor-specific MoS(2)-based nanoconjugates. Biomed Mater. 2021;16(5).","key":"121_CR104","DOI":"10.1088\/1748-605X\/ac15b1"},{"issue":"7","key":"121_CR105","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/sj.leu.2401074","volume":"12","author":"N Villamor","year":"1998","unstructured":"Villamor N, Zarco MA, Rozman M, et al. Acute myeloblastic leukemia with minimal myeloid differentiation: phenotypical and ultrastructural characteristics. Leukemia. 1998;12(7):1071\u20131075.","journal-title":"Leukemia."},{"issue":"7","key":"121_CR106","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1038\/s41375-021-01253-x","volume":"35","author":"N Daver","year":"2021","unstructured":"Daver N, Alotaibi AS, Bucklein V, et al. T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments. Leukemia. 2021;35(7):1843\u20131863.","journal-title":"Leukemia."},{"issue":"10","key":"121_CR107","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/s41571-020-0387-x","volume":"17","author":"SP Haen","year":"2020","unstructured":"Haen SP, Loffler MW, Rammensee HG, et al. Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire. Nat Rev Clin Oncol. 2020;17(10):595\u2013610.","journal-title":"Nat Rev Clin Oncol."},{"issue":"2","key":"121_CR108","doi-asserted-by":"publisher","first-page":"515","DOI":"10.3390\/ijms21020515","volume":"21","author":"RC Abbott","year":"2020","unstructured":"Abbott RC, Cross RS, Jenkins MR. Finding the Keys to the CAR: Identifying Novel Target Antigens for T Cell Redirection Immunotherapies. Int J Mol Sci. 2020;21(2):515.","journal-title":"Int J Mol Sci."},{"key":"121_CR109","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.583287","volume":"11","author":"R Minati","year":"2020","unstructured":"Minati R, Perreault C, Thibault P. A Roadmap Toward the Definition of Actionable Tumor-Specific Antigens. Front Immunol. 2020;11:583287.","journal-title":"Front Immunol."},{"issue":"10","key":"121_CR110","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1038\/s43018-023-00634-8","volume":"4","author":"A Apavaloaei","year":"2023","unstructured":"Apavaloaei A, Perreault C. Immunotargeting of a recurrent AML-specific neoantigen. Nat Cancer. 2023;4(10):1403\u20131405.","journal-title":"Nat Cancer."},{"issue":"10","key":"121_CR111","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1038\/s43018-023-00642-8","volume":"4","author":"E Giannakopoulou","year":"2023","unstructured":"Giannakopoulou E, Lehander M, Virding CS, et al. A T cell receptor targeting a recurrent driver mutation in FLT3 mediates elimination of primary human acute myeloid leukemia in vivo. Nat Cancer. 2023;4(10):1474\u20131490.","journal-title":"Nat Cancer."},{"doi-asserted-by":"crossref","unstructured":"Reynisson B, Alvarez B, Paul S, et al. NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. Nucleic Acids Res. 2020;48(W1):W449\u2013W454.","key":"121_CR112","DOI":"10.1093\/nar\/gkaa379"},{"issue":"4","key":"121_CR113","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1093\/bib\/bbz051","volume":"21","author":"S Mei","year":"2020","unstructured":"Mei S, Li F, Leier A, et al. A comprehensive review and performance evaluation of bioinformatics tools for HLA class I peptide-binding prediction. Brief Bioinform. 2020;21(4):1119-1135.","journal-title":"Brief Bioinform."},{"key":"121_CR114","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.3389\/fimmu.2020.01803","volume":"11","author":"I Springer","year":"2020","unstructured":"Springer I, Besser H, Tickotsky-Moskovitz N, et al. Prediction of Specific TCR-Peptide Binding From Large Dictionaries of TCR-Peptide Pairs. Front Immunol. 2020;11:1803.","journal-title":"Front Immunol."},{"doi-asserted-by":"crossref","unstructured":"Tan X, Li D, Huang P, et al. dbPepNeo: a manually curated database for human tumor neoantigen peptides. Database (Oxford). 2020;2020:baaa004.","key":"121_CR115","DOI":"10.1093\/database\/baaa004"},{"issue":"8","key":"121_CR116","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1038\/s41423-021-00717-5","volume":"18","author":"R Liu","year":"2021","unstructured":"Liu R, Jiang W, Mellins ED. Yeast display of MHC-II enables rapid identification of peptide ligands from protein antigens (RIPPA). Cell Mol Immunol. 2021;18(8):1847\u20131860.","journal-title":"Cell Mol Immunol."},{"key":"121_CR117","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.3389\/fimmu.2020.01804","volume":"11","author":"P van Balen","year":"2020","unstructured":"van Balen P, Jedema I, van Loenen MM, et al. HA-1H T-Cell Receptor Gene Transfer to Redirect Virus-Specific T Cells for Treatment of Hematological Malignancies After Allogeneic Stem Cell Transplantation: A Phase 1 Clinical Study. Front Immunol. 2020;11:1804.","journal-title":"Front Immunol."},{"issue":"18","key":"121_CR118","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1182\/blood-2017-06-791202","volume":"130","author":"I Tawara","year":"2017","unstructured":"Tawara I, Kageyama S, Miyahara Y, et al. Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS. Blood. 2017;130(18):1985\u20131994.","journal-title":"Blood."},{"issue":"6","key":"121_CR119","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.3390\/biomedicines11061724","volume":"11","author":"D Damiani","year":"2023","unstructured":"Damiani D, Tiribelli M. Checkpoint Inhibitors in Acute Myeloid Leukemia. Biomedicines. 2023;11(6):1724.","journal-title":"Biomedicines."},{"issue":"1","key":"121_CR120","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41375-021-01350-x","volume":"36","author":"S Tettamanti","year":"2022","unstructured":"Tettamanti S, Pievani A, Biondi A, et al. Catch me if you can: how AML and its niche escape immunotherapy. Leukemia. 2022;36(1):13\u201322.","journal-title":"Leukemia."},{"issue":"1","key":"121_CR121","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","volume":"7","author":"S Das","year":"2019","unstructured":"Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer. 2019;7(1):306.","journal-title":"J Immunother Cancer."},{"issue":"11","key":"121_CR122","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1158\/2159-8290.CD-22-0332","volume":"12","author":"NG Daver","year":"2022","unstructured":"Daver NG, Maiti A, Kadia TM, et al. TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions. Cancer Discov. 2022;12(11):2516\u20132529.","journal-title":"Cancer Discov."},{"key":"121_CR123","doi-asserted-by":"publisher","first-page":"609","DOI":"10.3389\/fphar.2019.00609","volume":"10","author":"D Liao","year":"2019","unstructured":"Liao D, Wang M, Liao Y, et al. A Review of Efficacy and Safety of Checkpoint Inhibitor for the Treatment of Acute Myeloid Leukemia. Front Pharmacol. 2019;10:609.","journal-title":"Front Pharmacol."},{"key":"121_CR124","doi-asserted-by":"publisher","first-page":"1108200","DOI":"10.3389\/fimmu.2023.1108200","volume":"14","author":"B Aru","year":"2023","unstructured":"Aru B, Pehlivanoglu C, Dal Z, et al. A potential area of use for immune checkpoint inhibitors: Targeting bone marrow microenvironment in acute myeloid leukemia. Front Immunol. 2023;14:1108200.","journal-title":"Front Immunol."},{"issue":"4","key":"121_CR125","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s11912-019-0781-7","volume":"21","author":"M Stahl","year":"2019","unstructured":"Stahl M, Goldberg AD. Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: Novel Combinations and Therapeutic Targets. Curr Oncol Rep. 2019;21(4):37.","journal-title":"Curr Oncol Rep."},{"key":"121_CR126","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.882531","volume":"12","author":"M Gomez-Llobell","year":"2022","unstructured":"Gomez-Llobell M, Peleteiro RA, Climent MJ, et al. Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: A Meta-Analysis. Front Oncol. 2022;12:882531.","journal-title":"Front Oncol."},{"issue":"9","key":"121_CR127","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1002\/cncr.31896","volume":"125","author":"P Williams","year":"2019","unstructured":"Williams P, Basu S, Garcia-Manero G, et al. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer. 2019;125(9):1470\u20131481.","journal-title":"Cancer."},{"issue":"1","key":"121_CR128","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13045-020-00853-x","volume":"13","author":"C Chen","year":"2020","unstructured":"Chen C, Liang C, Wang S, et al. Expression patterns of immune checkpoints in acute myeloid leukemia. J Hematol Oncol. 2020;13(1):28.","journal-title":"J Hematol Oncol."},{"issue":"14","key":"121_CR129","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.3390\/cells11142249","volume":"11","author":"Y Abaza","year":"2022","unstructured":"Abaza Y, Zeidan AM. Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes. Cells. 2022;11(14):2249.","journal-title":"Cells."},{"key":"121_CR130","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.590494","volume":"11","author":"ST Kim","year":"2020","unstructured":"Kim ST, Sheshadri A, Shannon V, et al. Distinct Immunophenotypes of T Cells in Bronchoalveolar Lavage Fluid From Leukemia Patients With Immune Checkpoint Inhibitors-Related Pulmonary Complications. Front Immunol. 2020;11:590494.","journal-title":"Front Immunol."},{"issue":"14","key":"121_CR131","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1002\/cncr.34229","volume":"128","author":"A Sheshadri","year":"2022","unstructured":"Sheshadri A, Goizueta AA, Shannon VR, et al. Pneumonitis after immune checkpoint inhibitor therapies in patients with acute myeloid leukemia: A retrospective cohort study. Cancer. 2022;128(14):2736\u20132745.","journal-title":"Cancer."},{"key":"121_CR132","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2019.116636","volume":"232","author":"D Gupta","year":"2019","unstructured":"Gupta D, Bhattacharjee O, Mandal D, et al. CRISPR-Cas9 system: A new-fangled dawn in gene editing. Life Sci. 2019;232:116636.","journal-title":"Life Sci."},{"issue":"1","key":"121_CR133","doi-asserted-by":"publisher","first-page":"8439","DOI":"10.1038\/s41467-024-52388-1","volume":"15","author":"T Bexte","year":"2024","unstructured":"Bexte T, Albinger N, Al AA, et al. CRISPR\/Cas9 editing of NKG2A improves the efficacy of primary CD33-directed chimeric antigen receptor natural killer cells. Nat Commun. 2024;15(1):8439.","journal-title":"Nat Commun."},{"issue":"9","key":"121_CR134","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1038\/s41375-023-01950-9","volume":"37","author":"S Neldeborg","year":"2023","unstructured":"Neldeborg S, Soerensen JF, Moller CT, et al. Dual intron-targeted CRISPR-Cas9-mediated disruption of the AML RUNX1-RUNX1T1 fusion gene effectively inhibits proliferation and decreases tumor volume in vitro and in vivo. Leukemia. 2023;37(9):1792\u20131801.","journal-title":"Leukemia."},{"issue":"4","key":"121_CR135","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.blre.2018.02.004","volume":"32","author":"A Thakur","year":"2018","unstructured":"Thakur A, Huang M, Lum LG. Bispecific antibody based therapeutics: Strengths and challenges. Blood Rev. 2018;32(4):339\u2013347.","journal-title":"Blood Rev."},{"key":"121_CR136","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.899468","volume":"13","author":"E Kubicka","year":"2022","unstructured":"Kubicka E, Lum LG, Huang M, et al. Bispecific antibody-targeted T-cell therapy for acute myeloid leukemia. Front Immunol. 2022;13:899468.","journal-title":"Front Immunol."},{"issue":"3","key":"121_CR137","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.ymthe.2019.12.014","volume":"28","author":"YA Yeung","year":"2020","unstructured":"Yeung YA, Krishnamoorthy V, Dettling D, et al. An Optimized Full-Length FLT3\/CD3 Bispecific Antibody Demonstrates Potent Anti-leukemia Activity and Reversible Hematological Toxicity. Mol Ther. 2020;28(3):889\u2013900.","journal-title":"Mol Ther."},{"issue":"1","key":"121_CR138","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12185-024-03793-1","volume":"120","author":"Y Imai","year":"2024","unstructured":"Imai Y. Novel treatment strategies for hematological malignancies in the immunotherapy era. Int J Hematol. 2024;120(1):3\u20135.","journal-title":"Int J Hematol."},{"key":"121_CR139","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2023.101073","volume":"60","author":"A Merino","year":"2023","unstructured":"Merino A, Maakaron J, Bachanova V. Advances in NK cell therapy for hematologic malignancies: NK source, persistence and tumor targeting. Blood Rev. 2023;60:101073.","journal-title":"Blood Rev."},{"issue":"4","key":"121_CR140","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s12185-024-03809-w","volume":"120","author":"S Saito","year":"2024","unstructured":"Saito S, Nakazawa Y. CAR-T cell therapy in AML: recent progress and future perspectives. Int J Hematol. 2024;120(4):455\u2013466.","journal-title":"Int J Hematol."},{"issue":"1","key":"121_CR141","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3390\/cells11010139","volume":"11","author":"K Panuciak","year":"2022","unstructured":"Panuciak K, Margas M, Makowska K, et al. Insights into Modern Therapeutic Approaches in Pediatric Acute Leukemias. Cells. 2022;11(1):139.","journal-title":"Cells."},{"issue":"1","key":"121_CR142","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007735","volume":"12","author":"C Ma","year":"2024","unstructured":"Ma C, Chen P, Du J, et al. Adoptive transfer of CMV-specific TCR-T cells for the treatment of CMV infection after haploidentical hematopoietic stem cell transplantation. J Immunother Cancer. 2024;12(1):e007735.","journal-title":"J Immunother Cancer."},{"issue":"3","key":"121_CR143","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.2668","volume":"8","author":"SM Durbin","year":"2025","unstructured":"Durbin SM, Zubiri L, Perlman K, et al. Late-Onset Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy. JAMA Netw Open. 2025;8(3):e252668.","journal-title":"JAMA Netw Open."},{"doi-asserted-by":"crossref","unstructured":"Perkin P, Sekmek S, Bayram D, et al. Pembrolizumab associated immune thrombocytopenia. J Chemother. 2025:1\u20135.","key":"121_CR144","DOI":"10.1080\/1120009X.2025.2468045"},{"key":"121_CR145","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.mrrev.2015.01.002","volume":"764","author":"H Shen","year":"2015","unstructured":"Shen H, McHale CM, Smith MT, et al. Functional genomic screening approaches in mechanistic toxicology and potential future applications of CRISPR-Cas9. Mutat Res Rev Mutat Res. 2015;764:31\u201342.","journal-title":"Mutat Res Rev Mutat Res."},{"key":"121_CR146","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2025.101152","volume":"63","author":"S Patel","year":"2025","unstructured":"Patel S, Jenkins E, Kusurkar RP, et al. Targeting BARD1 suppresses a Myc-dependent transcriptional program and tumor growth in pancreatic ductal adenocarcinoma. Neoplasia. 2025;63:101152.","journal-title":"Neoplasia."},{"issue":"1","key":"121_CR147","first-page":"52","volume":"32","author":"JC Man","year":"2024","unstructured":"Man JC, Cheng J, Zhao L. Effect of Knocking Out HOXA5 Gene by CRISPR-Cas9-Mediated Gene Editing Technique on Proliferation of Acute Myeloid Leukemia Cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi (Chinese). 2024;32(1):52\u201356.","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi (Chinese)."}],"container-title":["Current Medical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-025-00121-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11596-025-00121-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-025-00121-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T21:03:56Z","timestamp":1767042236000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11596-025-00121-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":147,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["121"],"URL":"https:\/\/doi.org\/10.1007\/s11596-025-00121-4","relation":{},"ISSN":["2096-5230","2523-899X"],"issn-type":[{"type":"print","value":"2096-5230"},{"type":"electronic","value":"2523-899X"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"assertion":[{"value":"16 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors report there are no competing interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval and Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}